The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Open accessAbstract
Males with X-linked severe combined immunodeficiency (XSCID) have defects in the common cytokine receptor γ chain (γ c ) gene that encodes a shared, essential component of the receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, and IL-15. The Janus family tyrosine kinase Jak3 is the only signaling molecule known to be associated with γ c , so it was hypothesized that defects in Jak3 might cause an XSCID-like phenotype. A girl with immunological features indistinguishable from those of XSCID was therefore selected for analysis. An Epstein-Barr virus (EBV)-transformed cell line derived from her lymphocytes had normal γ c expression but lacked Jak3 protein and had greatly diminished Jak3 messenger RNA. Sequencing revealed a different mutation on each allele: a single nucleotide insertion resulting in a frame shift and premature termination in the Jak3 JH4 domain and a nonsense mutation in the Jak3 JH2 domain. The lack of Jak3 expression correlated with impaired B cell signacrcling, as demonstrated by the inability of IL-4 to activate Stat6 in the EBV-transformed cell line from the patient. These observations indicate that the functions of γ c are dependent on Jak3 and that Jak3 is essential for lymphoid development and signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noguchi, M. (1993) · Cell · doi:10.1016/0092-8674(93)90167-o · Cited by 1,320
Self-citationInterleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-7 Receptor
Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., & Leonard, W. J. (1993) · Science · doi:10.1126/science.8266077 · Cited by 1,109
Self-citationDefective lymphoid development in mice lacking expression of the common cytokine receptor γ chain
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90047-0 · Cited by 1,038
Self-citationUtilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.
Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., & Anderson, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06576.x · Cited by 981
Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.
DiSanto, J. P., Müller, W., Guy-Grand, D., Fischer, A., & Rajewsky, K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.377 · Cited by 866
An Interleukin-4-Induced Transcription Factor: IL-4 Stat
Hou, J., Schindler, U., Henzel, W. J., Ho, T. C., Brasseur, M., & McKnight, S. L. (1994) · Science · doi:10.1126/science.8085155 · Cited by 854
Messenger RNA degradation in eukaryotes
Sachs, A. B. (1993) · Cell · doi:10.1016/0092-8674(93)80043-e · Cited by 846
Cloning of the γ Chain of the Human IL-2 Receptor
Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., & Sugamura, K. (1992) · Science · doi:10.1126/science.1631559 · Cited by 840
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752
Self-citationSharing of the Interleukin-2 (IL-2) Receptor γ Chain Between Receptors for IL-2 and IL-4
Kondo, M., Takeshita, T., Ishii, N., Nakamura, M., Watanabe, S., Arai, K.-I., & Sugamura, K. (1993) · Science · doi:10.1126/science.8266076 · Cited by 725
Cited by
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Self-citationThe JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Self-citationJAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Self-citationMechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Self-citationBanerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
“LOF TYK2 mutation causes a milder immunodeficiency characterized by susceptibility to viral infection [40, 41] because cells cannot respond to interferon (IFN)-c or IFNa/b [42].”
BackgroundJak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
“Analysis of patients with autosomal recessive forms of SCID unraveled that homozygous mutations of Jak3 can cause the disease (71, 79).”
BackgroundSelf-citationJAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
Self-citationInterleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
Self-citationNew insights into the regulation of T cells by γc family cytokines
Rochman, Y., Spolski, R., & Leonard, W. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2580 · Cited by 1,053
Self-citationTHE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling
Bach, E. A., Aguet, M., & Schreiber, R. D. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.563 · Cited by 1,034
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915
Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
Puel, A., Ziegler, S. F., Buckley, R. H., & Leonard., W. J. (1998) · Nature Genetics · doi:10.1038/3877 · Cited by 813
Self-citationConflict of Interest in Medical Research, Education, and Practice
(2009) · National Academies Press eBooks · doi:10.17226/12598 · Cited by 807
Liao, W., Lin, J.-X., & Leonard, W. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.08.003 · Cited by 745
Self-citationWaldmann, T. A., & Tagaya, Y. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.19 · Cited by 721
The JAK-STAT pathway at 30: Much learned, much more to do
Philips, R. L., Wang, Y., Cheon, H., Kanno, Y., Gadina, M., Sartorelli, V., Horvath, C. M., Darnell, J. E., Stark, G. R., & O’Shea, J. J. (2022) · Cell · doi:10.1016/j.cell.2022.09.023 · Cited by 720
Self-citationMinegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.009 · Cited by 702
Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined Immunodeficiency
Buckley, R. H., Schiff, S. E., Schiff, R. I., Markert, M. L., Williams, L. W., Roberts, J. L., Myers, L. A., & Ward, F. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400703 · Cited by 701
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Self-citationBiology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
Self-citationSTAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Defective Lymphoid Development in Mice Lacking Jak3
Nosaka, T., van Deursen, J. M. A., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C., & Ihle, J. N. (1995) · Science · doi:10.1126/science.270.5237.800 · Cited by 637
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O'Shea, J. J. (2004) · Genome Biology · doi:10.1186/gb-2004-5-12-253 · Cited by 635
Self-citationDEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUES
Fu, Y.-X., & Chaplin, D. D. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.399 · Cited by 616
Imada, K., & Leonard, W. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00018-3 · Cited by 610
Self-citationPrevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Self-citationClark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford, W. T., Laurence, A., Robinson, G. W., Shevach, E. M., Moriggl, R., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055756 · Cited by 575
Self-citationMechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 552
Self-citationKremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Buckley, R. H., Schiff, R. I., Schiff, S. E., Markert, M. L., Williams, L. W., Harville, T. O., Roberts, J. L., & Puck, J. M. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70199-9 · Cited by 540
Self-citationDefects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3
Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H., & Berg, L. J. (1995) · Science · doi:10.1126/science.270.5237.794 · Cited by 537
Buckley, R. H. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104614 · Cited by 532
Self-citationRAG Mutations in Human B Cell-Negative SCID
Schwarz, K., Gauss, G. H., Ludwig, L., Pannicke, U., Li, Z., Lindner, D., Friedrich, W., Seger, R. A., Hansen-Hagge, T. E., Desiderio, S., et al. (1996) · Science · doi:10.1126/science.274.5284.97 · Cited by 531
JAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Bernstein, I. L., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Kobrynski, L. J., Levinson, A. I., Mazer, B., Nelson, R. P., et al. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61142-8 · Cited by 521
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“Vincent and colleagues (2014) reported highly potent antiCD20-RIL-I immunocytokine targeting of established human B-cell lymphomas in severe combined immune deficiency (SCID) mice.”
BackgroundInterleukin-7: from bench to clinic
Fry, T. J., & Mackall, C. L. (2002) · Blood · doi:10.1182/blood.v99.11.3892 · Cited by 501
Human genetic susceptibility to infectious disease
Chapman, S. J., & Hill, A. V. S. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3114 · Cited by 499
Biology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
“Sub- sequently, JAK3 was shown to interact with the IL-2 receptor (IL-2R) common gamma chain (gc) in a region commonly mutated in patients suffering from severe combined immunodeficiency disease (SCID) (Russell et al. 1994).”
InfluentialJanus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation
Leonard, W. J., & Spolski, R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1688 · Cited by 441
Self-citationNFATc1 and NFATc2 Together Control Both T and B Cell Activation and Differentiation
Peng, S. L., Gerth, A. J., Ranger, A. M., & Glimcher, L. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00085-1 · Cited by 418
Hunter, T. (1998) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1998.0228 · Cited by 410
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
Self-citationStat5a/b are essential for normal lymphoid development and differentiation
Yao, Z., Cui, Y., Watford, W. T., Bream, J. H., Yamaoka, K., Hissong, B. D., Li, D., Durum, S. K., Jiang, Q., Bhandoola, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507350103 · Cited by 391
Self-citationCytokines and immunodeficiency diseases
Leonard, W. J. (2001) · Nature Reviews Immunology · doi:10.1038/35105066 · Cited by 390
Self-citationJaks, STATs, Cytokine Signal Transduction, and Immunoregulation: Are We There Yet?
O'Shea, J. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80505-1 · Cited by 386
Self-citationThe γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J.-X., & O'Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 383
Self-citationKovanen, P. E., & Leonard, W. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00203.x · Cited by 360
Self-citationLatent membrane protein 1of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
Gires, O. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3064 · Cited by 350
Myers, L. A., Patel, D. D., Puck, J. M., & Buckley, R. H. (2002) · Blood · doi:10.1182/blood.v99.3.872 · Cited by 344
Self-citationOccurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1122 · Cited by 344
DEVELOPMENT OF HUMAN LYMPHOID CELLS
Blom, B., & Spits, H. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090612 · Cited by 339
Differential Requirements for α4 Integrins during Fetal and Adult Hematopoiesis
Arroyo, A. G., Yang, J. T., Rayburn, H., & Hynes, R. O. (1996) · Cell · doi:10.1016/s0092-8674(00)81301-x · Cited by 335
Flanagan, M. E., Blumenkopf, T. A., Brissette, W. H., Brown, M. F., Casavant, J. M., Shang-Poa, C., Doty, J. L., Elliott, E. A., Fisher, M. B., Hines, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004286 · Cited by 334
The molecular regulation of Janus kinase (JAK) activation
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014) · Biochemical Journal · doi:10.1042/bj20140712 · Cited by 326
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Coskun, M., Salem, M., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 325
Inborn Errors of Human JAKs and STATs
Casanova, J.-L., Holland, S. M., & Notarangelo, L. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.016 · Cited by 320
Bao, L., Zhang, H., & Chan, L. S. (2013) · JAK-STAT · doi:10.4161/jkst.24137 · Cited by 320
Saharinen, P., & Silvennoinen, O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205156200 · Cited by 318
The Jak-Stat pathway in normal and perturbed hematopoiesis
Ward, A. C., Touw, I., & Yoshimura, A. (2000) · Blood · doi:10.1182/blood.v95.1.19 · Cited by 313
Kung, C., Pingel, J. T., Heikinheimo, M., Klemola, T., Varkila, K., Yoo, L. I., Vuopala, K., Poyhonen, M., Uhari, M., Rogers, M., et al. (2000) · Nature Medicine · doi:10.1038/73208 · Cited by 313
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Self-citationLiu, B. A., Jablonowski, K., Raina, M., Arcé, M., Pawson, T., & Nash, P. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.001 · Cited by 294
Clinical significance of Janus Kinase inhibitor selectivity
Choy, E. H. (2019) · Rheumatology · doi:10.1093/rheumatology/key339 · Cited by 285
Pellegrini, S., & Dusanter‐Fourt, I. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00615.x · Cited by 281
Development of αβ T cells in the human thymus
Spits, H. (2002) · Nature Reviews Immunology · doi:10.1038/nri913 · Cited by 279
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
The Jak-Stat Pathway: Cytokine Signalling from the Receptor to the Nucleus
Heim, M. H. (1999) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899909036638 · Cited by 271
Takemoto, S., Mulloy, J. C., Cereseto, A., Migone, T.-S., Patel, B. K. R., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J. D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13897 · Cited by 270
Self-citationFates of human B-cell precursors
LeBien, T. W. (2000) · Blood · doi:10.1182/blood.v96.1.9 · Cited by 266
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Hematopoietic cytokine receptor signaling
Baker, S. J., Rane, S. G., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210757 · Cited by 256
“The IL-2Rg-chain associates with Janus kinase-3 (JAK3) and mutations in either IL-2Rg-chain or JAK3 result in a non-functional receptor, which abrogates signaling via IL-2, IL-7, IL-9 and IL-15 (Russell et al., 1994, 1995).”
BackgroundPhotochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor
Thompson, J. E., Cubbon, R. M., Cummings, R. T., Wicker, L. S., Frankshun, R., Cunningham, B. R., Cameron, P. M., Meinke, P. T., Liverton, N., Weng, Y., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00106-3 · Cited by 234
Roifman, C. M., Zhang, J., Chitayat, D., & Sharfe, N. (2000) · Blood · doi:10.1182/blood.v96.8.2803 · Cited by 177
Thorarensen, A., Dowty, M. E., Banker, M. E., Juba, B., Jussif, J., Lin, T., Vincent, F., Czerwinski, R. M., Casimiro-Garcia, A., Unwalla, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01694 · Cited by 176
Back to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
Self-citationBehrmann (2004) · doi:10.1074/jbc.m404202200 · Cited by 98
Interactions of B-lymphocytes and bone cells in health and disease
Grčević, D., Sanjay, A., & Lorenzo, J. (2023) · Bone · doi:10.1016/j.bone.2021.116296 · Cited by 36
Klaeschen, A. S., Nümm, T. J., Herrmann, N., Leib, N., Maintz, L., Sakai, T., Wenzel, J., & Bieber, T. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.041 · Cited by 36
Metadata
- Authors
- Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., O'Shea, J. J., & Leonard, W. J.
- Venue
- Science
- Published
- 1995-11-03
- Volume
- 270
- Issue
- 5237
- Pages
- 797-800
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2038705787
- Cited by
- 803
- References
- 27
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.